METHODS
The methods of the REACH Registry have been published in detail previously. [7] [8] [9] [10] This protocol was submitted to institutional review boards in each country according to the local requirements and signed informed consent was required for all patients. Briefly, patients at least 45 years old with 3 or more risk factors for atherosclerosis and patients with established coronary artery disease, peripheral arterial disease, or cerebrovascular disease were enrolled. The multiple risk factors category consisted of diabetes, diabetic nephropathy, ankle-brachial index less than 0.9, asymptomatic carotid stenosis of 70% or more, carotid intima media thickness at least 2 times that at adjacent sites, systolic blood pressure of 150 mm Hg or higher despite treatment, hypercholesterolemia treated with medication, current smoking of 15 or more cigarettes per day, and age 65 years and older for men or 70 years and older for women.
Documented coronary artery disease consisted of 1 or more of the following: stable angina, history of unstable angina, history of percutaneous coronary intervention, history of coronary artery bypass grafting, or previous myocardial infarction.Documentedcerebrovasculardisease consisted of a neurologist report or hospital report with the diagnosis of ischemic stroke or transient ischemic attack. Documented peripheral artery disease consisted of current intermittent claudication with ankle-brachial index of less than 0.9 and/or a history of intermittent claudication together with a previous intervention, such as angioplasty, stenting, atherectomy, peripheral arterial bypass grafting, or other vascular interventions, including amputations. Diabetes was defined as any history of diabetes or current diabetes (diagnosed by at least 2 fasting blood glucose measures Ͼ126 mg/dL; to convert to mmol/L, multiply by 0.0555) treated with medication, lifestyle, or both.
Detailed information was collected at baseline, with subsequent annual followup at 1, 2, 3, and 4 years. 7, 9 Patients were enrolled between 2003 and 2004 and followed up until 2008. Final database lock was in April 2009. The initial follow-up was planned for up to 2 years and shortly before that point, an additional 2-year extension was proposed. Not all countries and sites that were in the 2-year followup cohort elected to continue participation in the registry, largely for financial reasons, although the majority did elect to continue. Countries and sites that decided not to participate in the 4-year follow-up were excluded from the results.
Event rates of cardiovascular death, myocardial infarction, stroke, and cardiovascular hospitalization were calculated. End points were not adjudicated. Cardiovascular death included fatal stroke, fatal myocardial infarction, or other cardiovascular death. Other cardiovascular death included other death of cardiac origin; pulmonary embolism; any sudden death including unobserved and unexpected death (eg, death while sleeping) unlessprovenotherwisebyautopsy;death following a vascular operation, vascular procedure, or amputation; death attributedtoheartfailure;deathfollowingavisceral or limb infarction; and any other death that could not be definitely attributed to a nonvascular cause or hemorrhage.Anymyocardialinfarctionorstroke followed by a death whatever the cause in the next 28 days was considered to be afatalmyocardialinfarctionorfatalstroke. Cardiovascular hospitalization consisted of hospitalization for unstable angina, transient ischemic attack, worsening of claudication related to peripheral artery disease, other ischemic arterial event, coronary artery bypass grafting, coronary angioplasty/stenting, carotid surgery, carotidangioplasty/stenting,amputationaffecting lower limbs, peripheral bypass graft, or angioplasty/stenting for peripheral artery disease.
Groups based on the enrollment criteria of risk factors only (for example, diabeticpatientswithoutestablisheddisease), stableatherosclerosis(withoutpriormyocardial infarction or stroke but with atherosclerosis established objectively, for example, patients with a history of revascularization), or prior ischemic events (myocardial infarction or stroke) were compared. On the case report form, the time of previous ischemic event was recorded as 1 year or less or longer than 1 year; no specific date of event was recorded. For the purposes of comparing event rates, patients were also classified as having diabetes or polyvascular disease at baseline. Polyvascular disease was defined as having atherothrombosis in 2 or 3 arterial beds (coronary, peripheral, cerebrovascular) at baseline. Allanalyseswereperformedonpatients eligible for the 4-year follow-up study, definedasallpatientswhocompletedatleast 1 postbaseline follow-up visit and who wereenrolledatcentersthatagreedtoparticipate in the 4-year follow-up study. Continuous variables are expressed as mean (standard deviation), and categorical variables are expressed as frequencies and percentages. Cumulative incidence 11 This method provides an alternative form for estimating survival rates from the Cox model. The cumulative incidence curves for cardiovascular death, myocardial infarction, or stroke were constructed using the Kaplan-Meier approach. Statistical significance was considered as a 2-sidedprobabilityoflessthan.05.Statistical analyses were performed using SAS version 9 (SAS Institute, Cary, North Carolina).
RESULTS
Of the 68 236 patients enrolled in the REACH Registry who had baseline data, 45 227 who were enrolled at 3647 centers in 29 countries were eligible for inclusion in the 4-year follow-up study and contributed4-yearoutcomesdata(20 980 patients enrolled at centers that did not participate in 4-year follow-up; 2029 patients did not return after baseline visit) (FIGURE 1).
The countries included were Austria (n=1458), Belgium (n=316), Brazil (n=331), Canada (n=1975), Chile (n = 244), China (n = 679), Taiwan (n = 764), Finland (n = 297), France (n=3904), Germany (n=4508), Greece (n=610), Hong Kong (n=171), Hungary (n = 926), Israel (n = 314), Japan (n=5073), Malaysia (n=417), Mexico (n = 801), the Netherlands (n = 305), Philippines (n = 985), Portugal (n = 209), Romania (n = 2005), Russia (n = 999), Spain (n = 1886), Switzerland (n = 632), Thailand (n = 506), United Arab Emirates (n=150), Ukraine (n = 596), the United Kingdom (n = 496), and the United States (n=13 670).
The baseline characteristics of the 45 227 patients and the medication use at 4 years in the 31 195 patients who had data at the 4-year follow-up are shown in TABLE 1. The patients' mean age was 68.4 years and approximately two-thirds were men. Hypertension (81.3%) and hypercholesterolemia (70.4%) were very common; diabetes 
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was present in 43.6% of patients. Polyvascular disease was present in 15.9% of patients; 48.4% had prior ischemic events, with 28.1% of those having an ischemic event within the previous year. A majority of patients were treated with antiplatelet and lipid-lowering therapies.
During the follow-up period, a total of 5481 patients experienced at least 1 event, including 2315 with cardiovascular death, 1228 with myocardial infarction, 1898 with stroke, and 40 with both a myocardial infarction and stroke reported on the case report form as occurring on the same day. (FIGURE 2) . The model described in Table 2 was refit using a 3-level factor for region: North America/Western Europe, Japan, and all other regions. Twoway interactions were fit between region and the 2 components of the diagnosis: duration of ischemia (3 levels: Յ1 year, Ͼ1 year, no ischemia) and type of disease (3 levels: polyvascular, single disease, risk factors only). Neither of these 2-way interactions was significant (P =.76 for duration of ischemia; P= .63 for type of disease). These results indicate that for the diagnosis variable, there was no evidence that the effect of this variable on cardiovascular death, myocardial infarction, or stroke differed by region. FIGURE 3 shows the event rates for patients with risk factors only (9.1%; 95% CI, 8.3%-9.9%), stable atherosclerosis without prior ischemic events (12.2%; 95% CI, 11.4%-12.9%), and those with prior ischemic events (18.3%; 95% CI, 17.4%-19.1%), and the TABLE 3 shows the event rates for patients with risk factors only, stable atherosclerosis without prior ischemic events (single/polyvascular disease), and prior ischemic events (single/ polyvascular disease). The total number of patients represents those eligible for the 4-year follow-up. The rates of the primary end point and its components are shown. The majority of deaths were due to cardiovascular causes in this population. Rates of cardiovascular hospitalization were high. The cumulative rate of cardiovascular death, myocardial infarction, stroke, or cardiovascular hospitalization ranged from 16.6% in the risk factor-only group to 47.1% in the patients with a baseline history of prior ischemic events and polyvascular disease. FIGURE 4 illustrates the additional risk of having an ischemic event during the year prior to enrollment vs more remotely in those patients with a history of an ischemic event at baseline. Those with a prior ischemic event in the past year had a significantly higher rate of cardiovascular death, myocardial infarction, or stroke than those with no ischemic event (HR, 1.71; 95% CI, 1.57-1.85; PϽ .001).

COMMENT
This analysis of a large international registry demonstrates that there are simple clinical predictors of future ischemic events in patients at various stages along the atherosclerotic continuum. Over the course of 4 years, easily demarcated subgroups of atherothrombotic patients had widely varying risks, ranging from 7% in nondiabetic patients with other risk factors for atherothrombosis to 25% in patients with polyvascular disease and prior ischemic events. This greater than 3-fold gradient in cumulative risk for cardiovascular death, myocardial infarction, or stroke illustrates that not all atherothrombosis is equal-an observation that the broad array of clinicians caring for these types of patients may find clinically relevant.
Patients with prior ischemic events at baseline were at higher risk than patients with stable atherosclerosis but without a history of ischemic events, who in turn were at higher risk than those patients with multiple risk factors only (with no evidence of established atherothrombosis). Among pa- 
Risk factors only
Ischemic events were defined as myocardial infarction (MI) or stroke. Diabetes status was missing for 3 patients: 2 patients in the category risk factors only and 1 patient in the category stable atherosclerosis without prior ischemic events. Error bars indicate 95% confidence intervals for each event rate; CV indicates cardiovascular. tients with a history of ischemic events, the occurrence of an ischemic event in the year before enrollment was a stronger predictor of future ischemic events than an ischemic event more than a year before enrollment in the registry. Notably, the effects of these factors on event rates within this registry were consistent for all geographic regions included without significant variation, and therefore these findings may be broadly applicable. Among all categories of patients, diabetes substantially increased the risk of future ischemic events. In those with established atherothrombosis, polyvascular disease was a particularly strong independent risk factor, even stronger than diabetes. These 2 factors were associated with significantly increased risk of the composite end point of cardiovascular death, myocardial infarction, or stroke as well as the individual components of this composite; in addition, they were associated with a significant increase in the risk of cardiovascular hospitalization. When included in the composite end point, cardiovascular hospitalization was associated with nearly doubling of the event rate in all subpopulations analyzed and tracked well with the more objective triple ischemic end point.
These findings should provide clinicians with improved estimates of their patients' future cardiovascular risk and thus enable more effective identification of patients who should be targeted for more intensive follow-up and therapy. Because the majority of patients in this registry would be candidates for basic secondary prevention, such as with statin therapy, future novel therapies may be optimally directed at those with higher levels of risk. 12 Thus, even in secondary prevention, simple risk stratification may be incrementally useful, especially as a host of new anti-atherosclerotic and antithrombotic therapies are being developed. New antiplatelet, anticoagulant, anti-atherosclerotic, and antiinflammatory agents will probably be expensive and may have additional adverse effects; thus, the ability to target these therapies to patients at highest ischemic risk will be desirable and likely would be cost-effective. Although other risk prediction tools have been developed that are effective in the setting of acute coronary syndromes, acute heart failure, or primary prevention, the ability to further risk-stratify patients for advanced secondary prevention will likely be of increasing importance in the future. [13] [14] [15] These findings also have potential implications for sample size determination for future clinical trials of therapies for atherothrombosis by helping identify those patients at highest risk who are most likely to benefit. For example, the discrepancy between diabetes trials targeting cardiovascular events and the low event rates in those trials illustrates the potential utility of the simple risk enrichment strategies found in the current analysis. 6 Planned trials of diabetic patients specifically designed to assess cardiovascular safety may find such simple enrichment strategies particularly useful to avoid low event rates that then create clinical uncertainty over whether diabetic agents provide cardiovascular benefit or harm. 16 The presence of established atherothrombosis was found to be a more potent predictor of risk than diabetes in patients with multiple risk factors, so it is not entirely the case that diabetes is an atherosclerosis risk equivalent, as older studies had suggested. 17, 18 Among patients with atherosclerosis, a history of ischemic events is a stronger predictor than diabetes or stable atherosclerosis, or the combination. Thus, in this analysis, the strongest predictor of future ischemic risk is a history of ischemic events, particularly in the prior year. The concomitant presence of diabetes or polyvascular disease in those patients further identifies an extremely high-risk population. 7, 9, 19, 20 The risk model in this analysis has a modest c statistic of 0.68, although this is not dissimilar from some other published cardiovascular risk scores that are in use. 13 Regardless, the main purpose of this analysis was to identify simple clinical descriptors of risk that clinicians could easily apply. Risk scores, despite being endorsed by professional society guidelines, are often not used in real-world practice, perhaps due to their perceived complexity with multiple variables. 21 The high rate of hospitalization for cardiovascular causes during follow-up is notable, especially due to the attendant economic costs generated. 22 Although high hospitalization rates have been recognized as a major problem for medical conditions such as heart failure, the present analysis highlights that patients with a history of, or with several risk factors for, atherothrombosis also have a high hospitalization rate. Even though the majority of patients attending their 4-year visit were treated with antithrombotic therapy and lipid-lowering therapy, the overall rates were not improved compared with the rates at baseline. 7 This persistent treatment gap may have contributed in part to their high hospitalization rates and may represent an opportunity to improve care.
Limitations to this analysis are those inherent to registries. 23 The follow-up of the initial cohort enrolled was incomplete because some centers and sites were unable to continue in the registry for financial reasons. Nevertheless, there was no evidence that the sites that dropped out were preferentially those with higher or lower ischemic risk, and therefore, there is no reason to think that the overall findings regarding event rates would have been significantly influenced. In fact, the primary end point event rate at 1 year was not significantly different in those with only 1-year follow-up vs those with 1-year and 4-year follow-up. An additional limitation is that end points were not adjudicated, although that is not unusual in a registry.
In conclusion, this analysis of a contemporary, international cohort of patients at various stages of atherothrombosis shows that there is a whole spectrum of ischemic risk in patients with risk factors or with established cardiovascular disease and that easily ascertainable clinical characteristics are the prominent factors associated with a high risk of future ischemic events. Polyvascular disease is the strongest predictor of future ischemic events; a history of previous ischemic events, particularly if such events occurred in the prior 12 months, and a diagnosis of diabetes each are strongly associated with further risk elevation. These findings may help in the identification of highrisk populations who may deserve intensive preventive efforts with novel therapies and also in the planning of future clinical trials.
